A study found that cost-effectiveness and clinical-effectiveness measures often point to the same treatment protocol.
Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
The effectiveness of new drugs is in decline, says an analysis, and researchers say comparative studies should look beyond efficacy measures.
A study highlights medical service trends among patients with high-deductible plans but lacks insight on health impact and long-term costs.
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
Members of the House Energy and Commerce committee alternatively blamed and excused the FDA over the meningitis outbreak that has killed 32 patients.
The drug industry gets a lot of grief over its online communications to consumers, but a study has found that sites posted by doctors and hospitals and touting surgeries are often dreadful—and far less tightly regulated.
About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest to patients.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.